Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison
Year: 2024
Type: article
Study design: Observational Study
Abstract: Background: Plasma phosphorylated-tau217 (p-tau217) has been shown to be one of the most accurate diagnostic markers for Alzheimer's disease (AD). No studies have compared the clinical performance of p-tau217 as assessed by the fully automated Lumipulse and SIMOA ALZpath p-tau217. Aim: To evaluate the diagnostic accuracy of Lumipulse and SIMOA plasma p-tau217 assays for AD. Methods: The study included 392 participants, 162 with AD, 70 with other neurodegenerative diseases (NDD) with CSF biomarkers and 160 healthy controls. Plasma p-tau217 levels were measured using the Lumipulse and ALZpath SIMOA assays. The ability of p-tau217 assessed by both techniques to discriminate AD from NDD and controls was investigated using ROC analyses. Results: Both techniques showed high internal consistency of p-tau217 with similar correlation with CSF p-tau181 levels. In head-to-head comparison, Lumipulse and SIMOA showed similar diagnostic accuracy for differentiating AD from NDD (area under the curve [AUC] 0.952, 95%CI 0.927-0.978 vs 0.955, 95%CI 0.928-0.982, respectively) and HC (AUC 0.938, 95%CI 0.910-0.966 and 0.937, 95% CI0.907-0.967 for both assays). Conclusions: This study demonstrated the high precision and diagnostic accuracy of p-tau217 for the clinical diagnosis of Alzheimer's disease using either fully automated or semi-automated techniques.
Source: Brain
Authors: Andrea Pilotto, Virginia Quaresima, Chiara Trasciatti, Chiara Tolassi, Diego Bertoli, Cristina Mordenti, Alice Galli, Andrea Rizzardi, Salvatore Caratozzolo, Andrea Zancanaro, José Contador, Oskar Hansson, Sebastian Palmqvist, Giovanni De Santis, Henrik Zetterberg, Kaj Blennow, Duilio Brugnoni, Marc Suárez-Calvet, Nicholas J Ashton, Alessandro Padovani
Institutions: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia, Pasqual Maragall Foundation, Barcelonaβeta Brain Research Center, Hospital Del Mar, Hospital del Mar Research Institute, Lund University, Skåne University Hospital, University of Gothenburg, University of Wisconsin–Madison, Sahlgrenska University Hospital, UK Dementia Research Institute, UCL Queen Square Institute of Neurology, University College London, University of Science and Technology of China, Sorbonne Université, Institut des Sciences Moléculaires, Pitié-Salpêtrière Hospital, Institut du Cerveau, Banner Sun Health Research Institute, Banner Alzheimer’s Institute
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,831
Funders: Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Eli Lilly and Company, Biogen, Familjen Erling-Perssons Stiftelse, Cure Alzheimer's Fund, Stiftelsen för Gamla Tjänarinnor, Prothena, GHR Foundation, André Losch Fondation, European Commission, Fondazione Cariplo, Ministero della Salute, Ministero dell’Istruzione, dell’Università e della Ricerca, Eisai, Hjärnfonden, Knut och Alice Wallenbergs Stiftelse, Novo Nordisk, Vetenskapsrådet, Alzheimerfonden, Siemens Healthineers, H. Lundbeck A/S, Grifols, Julius Clinical, UK Dementia Research Institute, Associazione Italiana Ricerca Alzheimer, Olav Thon Stiftelsen, National Institutes of Health, Parkinsonfonden, Horizon 2020 Framework Programme, Avid Radiopharmaceuticals, HORIZON EUROPE Framework Programme, European Research Council, Instituto de Salud Carlos III, UCLH Biomedical Research Centre, National Institute on Aging, H2020 Marie Skłodowska-Curie Actions
Awards: G1304444302, G1311708188, G1428335294, G1457535256, G1496489604, G150733400, G1588116593, G1771944843, Understanding Alzheimer Blood Biomarkers for Tau Pathology, G201353144, G2088087233, G2360966051, G237833635, G2385484910, G2700566569, G2733871257, The Alzheimer biomarker toolbox – use in pathogenic studies, diagnostics and theragnostics, G292763017, G303136745, G308275008, G3596610692, G3955935609, Junior Leader la Caixa Postdoctoral Fellowship Programme: Shaping the new generation of leaders in research, G4038479886, G4181244686, G420145614, G4489740550, G513711111, G521593840, G5304458214, Identification and validation of COmmon pathways at the CrOssrOads of neurodegeneration and Neuroprotection (COCOON), G5619554209, G5991094795, G6024075114, G6158734006, Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis, G6315092050, Prospective validation of high-performing blood biomarkers and digital cognitive tests in both specialist memory clinic and general primary care settings, G7153071485, Development of biomarkers in Alzheimer’s disease: improvement of early and accurate diagnosis and increased understanding of disease mechanisms that facilitates drug development, G7405691300, G749356836, G7598838153, G7731791180, G7829538610, El impacto clínico de los nuevos biomarcadores sanguíneos de Alzheimer: el estudio PLASMAR, G825904570, G86927839, G9000092144, G9000212218, The Longitudinal Course of Imaging Biomarkers in People At Risk for Alzheimer’s Disease, Wisconsin Registry for Alzheimer's Prevention
OpenAlex ID: W4405448010